Oestrogen replacement therapy lowers plasma levels of asymmetrical dimethylarginine in healthy postmenopausal women

Clinical Science

Volumn 105, Issue 1, 2003, Pages 67-71

  Teerlink, T ^a   Neele, S J M ^a   De Jong, S ^a   Netelenbos, J C ^a   Stehouwer, C D A ^b  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Asymmetrical dimethylarginine (ADMA); Atherosclerosis; Cardiovascular disease; Endothelial function; Nitric oxide; Oestrogen

Indexed keywords

CONJUGATED ESTROGEN; ESTROGEN RECEPTOR; N(G),N(G) DIMETHYLARGININE; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; PLACEBO; RALOXIFENE;

ADULT; ARTICLE; ATHEROSCLEROSIS; BIOAVAILABILITY; CARDIOVASCULAR RISK; CELL FUNCTION; CLINICAL ARTICLE; CLINICAL TRIAL; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG EFFECT; ENDOTHELIUM CELL; ESTROGEN THERAPY; FEMALE; HUMAN; HYPOTHESIS; HYSTERECTOMY; POSTMENOPAUSE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; STEREOISOMERISM;

ANALYSIS OF VARIANCE; ARGININE; CARDIOVASCULAR DISEASES; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DOUBLE-BLIND METHOD; ESTROGEN REPLACEMENT THERAPY; ESTROGENS, CONJUGATED (USP); FEMALE; HUMANS; HYSTERECTOMY; MIDDLE AGED; NITRIC OXIDE SYNTHASE; POSTMENOPAUSE; PROTEIN ISOFORMS; RALOXIFENE; RISK FACTORS; SELECTIVE ESTROGEN RECEPTOR MODULATORS; SENSITIVITY AND SPECIFICITY;

EID: 0038340435     PISSN: 01435221     EISSN: None     Source Type: Journal    
DOI: 10.1042/CS20020309     Document Type: Article

References (30)

1. Grady, D., Herrington, D., Bittner, V. et al. (2002) Cardiovascular disease outcomes during 6.8 years of hormone therapy: Heart and Estrogen/progestin Replacement Study follow-up (HERS II). JAMA, J. Am. Med. Assoc. 288, 49-57
2. Writing Group for the Women's Health Initiative Investigators. (2002) Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA, J. Am. Med. Assoc. 288, 321-333
3. Grodstein, F., Stampfer, M. J., Manson, J. E. et al. (1996) Postmenopausal estrogen and progestin use and the risk of cardiovascular disease. N. Engl. J. Med. 335, 453-461
4. de Valk-de Roo, G. W., Stehouwer, C. D., Meijer, P. et al. (1999) Both raloxifene and estrogen reduce major cardiovascular risk factors in healthy postmenopausal women: A 2-year, placebo-controlled study. Arterioscler. Thromb. Vasc. Biol. 19, 2993-3000
5. Mendelsohn, M. E. and Karas, R. H. (1999) The protective effects of estrogen on the cardiovascular system. N. Engl. J. Med. 340, 1801-1811
6. Sack, M. N., Rader, D. J. and Cannon, R. O. (1994) Oestrogen and inhibition of oxidation of low-density lipoproteins in postmenopausal women. Lancet 343, 269-270
7. Shwaery, G. T., Vita, J. A. and Keaney, J. F. (1997) Antioxidant protection of LDL by physiological concentrations of 17 beta-estradiol. Requirement for estradiol modification. Circulation 95, 1378-1385
8. Mijatovic, V., Netelenbos, C., van der Mooren, M. J., de Valk-de Roo GW, Jakobs, C. and Kenemans, P. (1998) Randomized, double-blind, placebo-controlled study of the effects of raloxifene and conjugated equine estrogen on plasma homocysteine levels in healthy postmenopausal women. Fertil. Steril. 70, 1085-1089
9. Walsh, B. W., Paul, S., Wild, R. A. et al. (2000) The effects of hormone replacement therapy and raloxifene on C-reactive protein and homocysteine in healthy postmenopausal women: a randomized, controlled trial. J. Clin. Endocrinol. Metab. 85, 214-218
10. Gilligan, D. M., Badar, D. M., Panza, J. A., Quyyumi, A. A. and Cannon, R. O. (1994) Acute vascular effects of estrogen in postmenopausal women. Circulation 90, 786-791
11. Vehkavaara, S., Hakala-Ala-Pietilä, T., Virkamäki, A. et al. (2000) Differential effects of oral and transdermal estrogen replacement therapy on endothelial function in postmenopausal women. Circulation 102, 2687-2693
12. Imthurn, B., Rosselli, M., Jaeger, A. W., Keller, P. J. and Dubey, R. K. (1997) Differential effects of hormone-replacement therapy on endogenous nitric oxide (nitrite/nitrate) levels in postmenopausal women substituted with 17 beta-estradiol valerate and cyproterone acetate or medroxyprogesterone acetate. J. Clin. Endocrinol. Metab. 82, 388-394
13. Mikkola, T., Viinikka, L. and Ylikorkala, O. (1998) Estrogen and postmenopausal estrogen/progestin therapy: effect on endothelium-dependent prostacyclin, nitric oxide and endothelin-1 production. Eur. J. Obstet. Gynecol. Reprod. Biol. 79, 75-82
14. Vallance, P., Leone, A., Calver, A., Collier, J. and Moncada, S. (1992) Accumulation of an endogenous inhibitor of nitric oxide synthesis in chronic renal failure. Lancet 339, 572-575
15. Böger, R. H., Bode-Böger, S. M., Szuba, A. et al. (1998) Asymmetric dimethylarginine (ADMA): a novel risk factor for endothelial dysfunction: its role in hypercholesterolemia. Circulation 98, 1842-1847
16. Miyazaki, H., Matsuoka, H., Cooke, J. P. et al. (1999) Endogenous nitric oxide synthase inhibitor: a novel marker of atherosclerosis. Circulation 99, 1141-1146
17. Cooke, J. P. (2000) Does ADMA cause endothelial dysfunction? Arterioscler. Thromb. Vasc. Biol. 20, 2032-2037
18. Valkonen, V. P., Päivä, H., Salonen, J. T. et al. (2001) Risk of acute coronary events and serum concentration of asymmetrical dimethylarginine. Lancet 358, 2127-2128
19. Holden, D. P., Fickling, S. A., Whitley, G. S. and Nussey, S. S. (1998) Plasma concentrations of asymmetric dimethylarginine, a natural inhibitor of nitric oxide synthase, in normal pregnancy and preeclampsia. Am. J. Obstet. Gynecol. 178, 551-556
20. Teerlink, T., Nijveldt, R. J., de Jong, S. and van Leeuwen, P. A. (2002) Determination of arginine, asymmetric dimethylarginine, and symmetric dimethylarginine in human plasma and other biological samples by high-performance liquid chromatography. Anal. Biochem. 303, 131-137
21. Leiper, J. M., Santa Maria, J, Chubb, A. et al. (1999) Identification of two human dimethylarginine dimethylaminohydrolases with distinct tissue distributions and homology with microbial arginine deiminases. Biochem. J. 343, 209-214
22. Marescau, B., Nagels, G., Possemiers, I. et al. (1997) Guanidino compounds in serum and urine of nondialyzed patients with chronic renal insufficiency. Metab. Clin. Exp. 46, 1024-1031
23. Murray-Rust, J., Leiper, J., McAlister, M. et al. (2001) Structural insights into the hydrolysis of cellular nitric oxide synthase inhibitors by dimethylarginine dimethylaminohydrolase. Nat. Struct. Biol. 8, 679-683
24. Ito, A., Tsao, P. S., Adimoolam, S., Kimoto, M., Ogawa, T. and Cooke, J. P. (1999) Novel mechanism for endothelial dysfunction: dysregulation of dimethylarginine dimethylaminohydrolase. Circulation 99, 3092-3095
25. Böger, R. H., Sydow, K., Borlak, J. et al. (2000) LDL cholesterol upregulates synthesis of asymmetrical dimethylarginine in human endothelial cells: involvement of S-adenosylmethionine-dependent methyltransferases. Circ. Res. 87, 99-105
26. Abplanalp, W., Scheiber, M. D., Moon, K., Kessel, B., Liu, J. H. and Subbiah, M. T. (2000) Evidence for the role of high density lipoproteins in mediating the antioxidant effect of estrogens. Eur. J. Endocrinol. 142, 79-83
27. Tikkanen, M. J., Vihma, V., Jauhiainen, M., Höckerstedt, A., Helisten, H. and Kaamanen, M. (2002) Lipoprotein-associated estrogens. Cardiovasc. Res. 56, 184-188
28. Walsh, B. W., Kuller, L. H., Wild, R. A. et al. (1998) Effects of raloxifene on serum lipids and coagulation factors in healthy postmenopausal women. JAMA, J. Am. Med. Assoc. 279, 1445-1451
29. Stühlinger, M. C., Tsao, P. S., Her, J. H., Kimoto, M., Balint, R. F. and Cooke, J. P. (2001) Homocysteine impairs the nitric oxide synthase pathway: role of asymmetric dimethylarginine. Circulation 104, 2569-2575
30. Böger, R. H., Lentz, S. R., Bode-Böger, S. M., Knapp, H. R. and Haynes, W. G. (2001) Elevation of asymmetrical dimethylarginine may mediate endothelial dysfunction during experimental hyperhomocyst(e)inaemia in humans. Clin. Sci. 100, 161-167